Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
1(11%)
Results Posted
100%(6 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_1
1
11%
Ph phase_2
6
67%
Ph phase_4
2
22%

Phase Distribution

1

Early Stage

6

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
6(66.7%)
Phase 4Post-market surveillance
2(22.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(6)
Terminated(1)
Other(1)

Detailed Status

Completed6
unknown1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (11.1%)
Phase 26 (66.7%)
Phase 42 (22.2%)

Trials by Status

unknown111%
recruiting111%
terminated111%
completed667%

Recent Activity

1 active trials
Showing 5 of 9
completedphase_2

REPOSE Study: Reducing Delirium by Enhancing Postoperative Sleep With Suvorexant

NCT05733286
recruitingphase_2

Sleep Trial to Prevent Alzheimer's Disease

NCT04629547
completedphase_4

Suvorexant and Sleep/Delirium in ICU Patients

NCT04092894
completedphase_2

Suvorexant to Reduce Symptoms of Nicotine Use

NCT04234997
completedphase_2

The Efficacy of Suvorexant in Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial

NCT03412591
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05733286Phase 2

REPOSE Study: Reducing Delirium by Enhancing Postoperative Sleep With Suvorexant

Completed
NCT04629547Phase 2

Sleep Trial to Prevent Alzheimer's Disease

Recruiting
NCT04092894Phase 4

Suvorexant and Sleep/Delirium in ICU Patients

Completed
NCT04234997Phase 2

Suvorexant to Reduce Symptoms of Nicotine Use

Completed
NCT03412591Phase 2

The Efficacy of Suvorexant in Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial

Completed
NCT03999099Phase 1

Targeting Orexin to Treat Nicotine Dependence

Unknown
NCT04229095Phase 2

Medication Development in Alcoholism: Suvorexant Versus Placebo

Completed
NCT03897062Phase 2

Suvorexant in the Management Comorbid Sleep Disorder and Alcohol Dependence

Terminated
NCT03312517Phase 4

Study to Compare the Awakening Threshold Effects of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9